Searchable abstracts of presentations at key conferences in endocrinology

ea0010p40 | Endocrine tumours and neoplasia | SFE2005

The RET mutation E768D confers a late onset FMTC-only phenotype with incomplete penetrance

McCall D , Dabir T , Russell C , Morrison P , Hunter S

Mutations of the RET proto-oncogene are associated with MEN and FMTC and aid diagnosis and predictive testing in family members. Genotype-phenotype correlations are also used to plan therapeutic decisions. We describe a 4 generation family with a rare E768D mutation in exon 13. The index case was diagnosed with MTC at age 54 and remains free of clinical disease 11 years following thyroidectomy and neck irradiation. 2 further family members were identified with MTC at age 25 an...

ea0011p500 | Endocrine tumours and neoplasia | ECE2006

Development of dopamine agonist resistance and progression from microadenoma to macroadenoma in two women with hyperprolactinaemia

McCall D , Hunter SJ , Cooke RS , Herron B , Sheridan B , Atkinson AB

Dopamine agonist therapy is an effective long-term treatment in >90% of patients with hyperprolactinaemia, controlling both prolactin secretion and tumour growth. We describe the unusual late emergence of resistance to high-dose dopamine agonist treatment in two recent female patients. Both women presented with secondary amenorrhoea, were shown to have high prolactin levels and a pituitary microadenoma. Each had an excellent initial response to bromocriptine but years late...